Published in final edited form as:

Eur J Epidemiol. 2015 October ; 30(10): 1129–1135. doi:10.1007/s10654-015-0088-4.

Molecular Pathological Epidemiology Gives Clues to Paradoxical Findings

Reiko Nishihara^{a,b,c}, Tyler J. VanderWeele^{d,e}, Kenji Shibuya^c, Murray A. Mittleman^{d,f}, Molin Wang^{d,e,g}, Alison E. Field^{d,g,h,i}, Edward Giovannucci^{a,d,g}, Paul Lochhead^{i,j}, and Shuji Ogino^{b,d,k}

^aDepartment of Nutrition, Harvard T.H. Chan School of Public Health, 655 Huntington Ave., Boston, Massachusetts 02115 USA

^bDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave., Boston, Massachusetts 02215 USA

^cDepartment of Global Health Policy, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan

^dDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington Ave., Boston, Massachusetts 02115 USA

^eDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, 677 Huntington Ave., Boston, Massachusetts 02115 USA

^fCardiovascular Epidemiology Research Unit, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, 375 Longwood Ave., Boston, Massachusetts, USA

^gChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Ave., Boston, Massachusetts 02115 USA

^hDivision of Adolescent Medicine, Boston Children's Hospital, 300 Longwood Ave., Boston, Massachusetts 02115 USA

ⁱDepartment of Epidemiology, Brown University, 121 South Main Street, Providence, Rhode Island 02912 USA

^jDivision of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts

^kDepartment of Pathology, Brigham and Women's Hospital, Boston and Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115 USA

Abstract

Co-corresponding Authors: Reiko Nishihara, PhD, Department of Nutrition, Harvard T.H. Chan School of Public Health, 665 Huntington Ave., Bldg. 2, Room 304, Boston, Massachusetts 02115 USA, Tel: 1-617-432-1838, Fax: 1-617-432-2435, rnishiha@hsph.harvard.edu, Shuji Ogino, MD, PhD, MS, Department of Epidemiology, Harvard T.H. Chan School of Public Health, 450 Brookline Ave., DFCI Room M422, Boston, Massachusetts 02215 USA, Tel: 1-617-632-1972, Fax: 1-617-582-8558, shuji_ogino@dfci.harvard.edu.

Use of standardized official symbols: Use of standardized official symbols: We use HUGO (Human Genome Organisation)-approved official symbols for genes and gene products, including BRAF, FASN, KRAS, MGMT, and SMAD7; all of which are described at www.genenames.org

Conflict of interest: All authors declare that they have no conflicts of interest.

A number of epidemiologic studies have described what appear to be paradoxical associations, where an incongruous relationship is observed between a certain well-established risk factor for disease incidence and favorable clinical outcome among patients with that disease. For example, the “obesity paradox” represents the association between obesity and better survival among patients with a certain disease such as coronary heart disease. Paradoxical observations cause vexing clinical and public health problems as they raise questions on causal relationships and hinder the development of effective interventions. Compelling evidence indicates that pathogenic processes encompass molecular alterations within cells and the microenvironment, influenced by various exogenous and endogenous exposures, and that interpersonal heterogeneity in molecular pathology and pathophysiology exists among patients with any given disease. In this article, we introduce methods of the emerging integrative interdisciplinary field of molecular pathological epidemiology (MPE), which is founded on the unique disease principle and disease continuum theory. We analyze and decipher apparent paradoxical findings, utilizing the MPE approach and available literature data on tumor somatic genetic and epigenetic characteristics. Through our analyses in colorectal cancer, renal cell carcinoma, and glioblastoma (malignant brain tumor), we can readily explain paradoxical associations between disease risk factors and better prognosis among disease patients. The MPE paradigm and approach can be applied to not only neoplasms but also various non-neoplastic diseases where there exists indisputable ubiquitous heterogeneity of pathogenesis and molecular pathology. The MPE paradigm including consideration of disease heterogeneity plays an essential role in advancements of precision medicine and public health.

Keywords

bias; cardiovascular disease; molecular diagnostics; multifactorial diseases; personalized medicine

INTRODUCTION

An apparently paradoxical association, which is occasionally observed in epidemiologic research, refers to the relationship of a well-known risk factor (e.g., obesity) for developing a certain disease (e.g., coronary heart disease) with lower mortality among patients with that disease. Intuitively, we tend to consider that a disease risk factor is likely associated with worse clinical outcomes among patients with that disease, because the risk factor is considered to facilitate the pathogenic process that has led to the disease. In the notorious “obesity paradox” which has been described in various diseases [1–5], obese patients with a given disease in average experience better clinical outcomes than normal-weight patients, despite the fact that obesity is a well-established risk factor for that disease. Possible explanations to the paradox have been proposed, including selection bias, index event bias, collider bias, unmeasured confounding, measurement error, and reverse causation [5–11]. However, possible biological mechanisms which may provide an additional plausible explanation have not been well discussed.

The purpose of this article is to demonstrate that, by means of considering molecular heterogeneity of disease based on pathogenic mechanisms, we can readily decipher some of apparent paradoxical findings. Collapsing two or more heterogeneous disease subtypes into one disease entity would produce a similar problem as unmeasured confounding in the

structure of the association between a risk factor and mortality [12]. This phenomenon (bias due to unmeasured molecular subtypes of disease) has been termed “molecular confounding” though it does not satisfy all of the criteria of typical confounding in an epidemiologic sense [13]. We use examples of studies on colorectal, kidney, and brain cancers, to demonstrate that the inherent nature of inter-personal molecular heterogeneity within a disease can underlie paradoxical observations. These examples attest to the importance of taking disease heterogeneity and pathogenesis into consideration in not only research but also clinical and public health practice [14]. This trend has also been highlighted by the precision medicine initiative of the U.S.A. National Institute of Health [15].

MOLECULAR PATHOLOGICAL EPIDEMIOLOGY (MPE): ANALYSIS

METHOD

Accumulating evidence indicates that many traditional disease designations (e.g., lung, breast, or colorectal cancer, heart failure, type 2 diabetes mellitus, hypertension, kidney stones, major depression, stroke, or multiple sclerosis) are umbrella terms for a group of heterogeneous disease processes which share certain common features, such as clinical manifestations and some pathologic characteristics [16]. However, it is increasingly evident that, in each individual, disease processes represent unique sets of molecular changes in cells and microenvironment, and these processes differ from person to person [17]. Furthermore, a disease process is influenced by endogenous and exogenous exposures (e.g., germline genetics, diet, microorganisms, medications, and inhalants) and molecular interactions in the microenvironment [17]. Endogenous and exogenous exposures certainly vary from person to person [17]. Therefore, while there are some similarities between people with a particular disease, each individual has a unique disease process which is different from any other individuals (i.e., the unique disease principle) [17]. The fundamental tenet of MPE is that inherent pathogenic heterogeneity is taken into account when we examine the association between a risk factor and disease incidence. Here, we introduce the emerging field of molecular pathological epidemiology (MPE), and discuss the importance of considering pathogenesis and inherent heterogeneity of disease.

By identifying groups of patients who share similar molecular pathologic signatures, molecular classification of disease plays a key role in integrating the unique disease principle into epidemiologic research [17]. MPE has recently emerged to facilitate this integration of molecular pathology into epidemiology [18]. MPE is defined as epidemiology of molecular pathology and heterogeneity of disease. MPE research emphasizes the importance of considering disease heterogeneity and the complexity of pathogenic mechanisms by examining hypothetical links between exposures and molecular signatures of the disease [19]. The MPE approach can not only uncover associations between exposures and specific molecular subtypes of disease but also refine risk estimates specific for disease subtypes, thereby providing insight into pathogenic mechanisms and contributing to causal inference [17–21]. The MPE approach and concept have been widely accepted and utilized [22–47]. MPE has been a major theme of international symposia [14, 48, 49] and recently-established international meeting series [50].

It is relevant to briefly review molecular pathology of colorectal cancer, because paradoxical findings exist in colorectal cancer and ample data from both conventional epidemiology and MPE research actually give us clues to the paradoxes. Colorectal cancer is a heterogeneous group of neoplasms which arise as a result of accumulation of a differing set of molecular alterations [51–53]. In the initiation and progression of colorectal neoplasia, aberrant cellular genetic and epigenetic changes occur along with stromal microenvironmental changes [51, 54]. Some pathogenic molecular alterations in colorectal cancer including microsatellite instability (MSI), and somatic mutations in *KRAS* and *BRAF* are now routinely tested for clinical use [55]. With these well-established molecular pathology tests, colorectal cancer represents a disease area where MPE research has been quite active. Emerging evidence indicates that specific exposures influence the initiation and progression of different molecular subtypes of colorectal tumor [20]. For example, MPE research has shown that cigarette smoking has been associated with an increased risk for colorectal cancer subtype characterized by high-level CpG island methylator phenotype (CIMP-high) [56–58]. In addition, MPE research has suggested that colonoscopy screening may be less effective in reducing risks of CIMP-high and MSI-high subtypes, compared to non-CIMP-high and non-MSI-high subtypes [59]. These data suggest that optimal colonoscopy screening may vary among individuals with different lifestyle and genetic risk profiles. Hence, MPE research can contribute to the development of more personalized prevention strategies. In essence, “colorectal cancer” is a single disease entity in the conventional research paradigm, but consists of a complex group of conditions when we look deeply into molecular pathological signatures. A better understanding of disease heterogeneity is a prerequisite for accurate assessment of the associations between risk factors and pathologic processes.

In the following section, we analyze and decipher apparent paradoxical findings, utilizing the MPE approach and available literature data.

ANALYSES OF PARADOXES

Lynch syndrome, MSI-high colorectal cancer, and longer survival

Lynch syndrome is the most common form of hereditary colorectal cancer, and is caused by a germline mutation in one of DNA mismatch repair genes [60, 61]. Previous studies have reported that carriage of Lynch syndrome mutations is associated with markedly higher risk of colorectal cancer; but among all colorectal cancer patients, Lynch syndrome patients in average survive longer than other colorectal cancer patients [60, 61]. Studies have shown that Lynch syndrome mutation carriers have a higher risk of the MSI-high subtype of colorectal cancer (but not that of non-MSI subtype), and among colorectal cancer patients, the MSI-high subtype is associated with longer survival (Fig. 1a) [55]. Therefore, the seemingly paradoxical association between colorectal cancer patients carrying Lynch syndrome mutations and superior survival can be readily explained by the association between the specific cancer subtype (MSI-high) caused by Lynch syndrome and better prognosis.

***SMAD7* variant, low-stage colorectal cancer, and longer survival**

Genome-wide association studies indicate that the rs4939827 single nucleotide polymorphism (SNP) in *SMAD7* (18q21) is a well-validated susceptibility variant for colorectal cancer [62]. The major G allele of the rs4939827 polymorphism has been associated with higher incidence of colorectal cancer; but among colorectal cancer patients, the presence of this major allele is associated with better survival [63, 64]. A recent study has demonstrated that the major G allele of rs4939827 is associated with a high risk of low-stage (indolent and less invasive) colorectal cancer subtype [64]; these findings can explain the apparently paradoxical association of the risk variant with better survival among colorectal cancer patients (Fig. 1b).

Obesity, *FASN* non-upregulated renal cell carcinoma, and longer survival

Renal cell carcinoma (RCC, a specific pathologic type of kidney cancer) is another example where recent MPE data are available to help elucidate paradoxical findings, which fit the "obesity paradox". Obesity has been associated with risk of RCC, but also counter-intuitively with better survival among RCC patients [65]. A study by Hakimi et al. [66] has provided a helpful clue to this paradox; obesity is associated with low-stage RCC and low-grade RCC (less aggressive forms of RCC). Moreover, obesity is associated with a specific molecular subtype of RCC with no upregulation of *FASN* (the official symbol for fatty acid synthase) [66]. The *FASN* protein is a key enzyme in fatty acid metabolism [67]. Compared to RCCs with *FASN* upregulation, RCCs without *FASN* upregulation are associated with longer survival [66]. Thus, obesity is associated with low-stage, low-grade, and *FASN* non-upregulated subtypes of RCC; all of which are features associated with longer survival in RCC patients (Fig. 1c).

***MGMT* promoter variant, loss of *MGMT* expression, and longer survival in glioblastoma**

The paradoxical observation in the association between a *MGMT* promoter variant, a risk factor for glioblastoma, and longer patient survival was explained by MPE studies. *MGMT* is DNA repair enzyme, and functions as a tumor suppressor. In some cancers, *MGMT* expression is lost, through DNA hypermethylation at its promoter CpG island. Loss of *MGMT* expression is causally linked to mismatch repair deficiency and carcinogenesis [68]. The minor T allele of the rs16906252 SNP in the *MGMT* promoter is associated with longer patient survival in glioblastoma (a common pathologic type of brain cancer) [69]. This is paradoxical, because the minor T allele of this SNP has been causally linked to carcinogenesis, through *MGMT* promoter methylation and loss of expression [70, 71]. However, this paradox can be easily explained, as studies have shown that *MGMT* promoter CpG island methylation and loss of *MGMT* expression are associated with longer survival in glioblastoma [68, 69]. Essentially, the minor T allele of the SNP is a cause of the indolent tumor molecular subtype with *MGMT* promoter CpG island methylation and loss of *MGMT* expression in glioblastoma. Thus, the apparent paradoxical association can be explained by disease heterogeneity in glioblastoma (Fig. 1d).

DISCUSSION

The above analyses illustrate how inherent heterogeneity of disease can readily explain paradoxical findings, utilizing the molecular pathological epidemiology (MPE) approach and available literature data. Under the MPE paradigm, a risk factor for a disease likely facilitates specific pathogenic processes, thereby influencing occurrence of a specific disease subtype, which is often associated with clinical outcome among patients with the disease (consisting of the specific subtype and other subtypes). Without considering heterogeneous disease subtypes, the associations depicted in Fig. 1 can appear as paradoxes. In another setting, if a disease risk factor is linked with occurrence of an aggressive disease subtype, the risk factor is most likely associated with both disease occurrence and adverse prognosis among disease patients; hence, there is no paradox.

MPE research has been mostly applied to neoplastic diseases where tumor molecular tests have been widely available in research as well as clinical practice [16, 72]. In contrast, for most non-neoplastic diseases, disease molecular pathology data remain scanty, and the emerging MPE paradigm has not yet been widely applied. However, accumulating evidence indicates that, in many non-neoplastic diseases (including obesity, metabolic diseases, cardiovascular diseases, respiratory diseases, infectious diseases, immunity-related diseases, neurological diseases, psychiatric diseases, etc.), there exists inherent heterogeneity of pathogenesis [16]. Therefore, the relevance of the MPE paradigm in non-neoplastic diseases has been increasingly recognized [16, 73–75]. Hence, we speculate that, perhaps together with the other recognized causes of paradoxes, disease heterogeneity can contribute to some of reported paradoxical findings in not only neoplastic diseases but also non-neoplastic diseases. For example, recently, Lajous et al. [6] have suggested that type 2 diabetes mellitus may consist of different subtypes, and that the paradoxical finding on better survival among diabetic patients could result from the heterogeneity of the disease. As we do not generally consider subtypes of type 2 diabetes mellitus in practice, analysis limited to cases with type 2 diabetes mellitus (as one entity) will be conditioned on a collider, and then introduces selection bias [6]. Heart failure is another example of a complex disorder that results from diverse biological processes. Patients with heart failure comprise a heterogeneous group, and pathologic processes of heart failure are influenced by many factors, including hypertension, structural disorders of the pericardium, myocardium, endocardium or heart valves, vascular abnormalities, diabetes mellitus, other metabolic abnormalities, cigarette smoking, alcohol consumption, and kidney disease [76].

With the advent of molecular pathology tests and precision medicine [15, 77–79], molecular classification systems can be used to subgroup patients with similar pathogenic characteristics, to better predict disease evolution and response to intervention. As biomedical and public health sciences advance, modern epidemiology and clinical medicine should more explicitly take into account disease pathogenesis and inherent heterogeneity of disease [80–82]. The MPE concept and research can substantially contribute to the acceleration of precision medicine. We emphasize that a full assimilation of the MPE concept requires a change in mindsets of clinicians and researchers. Furthermore, the MPE concept has been expanding for recent years. The MPE field has recently been integrated with pharmacoepidemiology (to form pharmaco-MPE) [16], and with immunology (to form

immuno-MPE) [83]. In order to keep up epidemiology to advancement of biomedicine, we must address various challenges, which include difficulty in characterizing the complex nature of many multifactorial diseases, paucity of data on their molecular subtyping, and paucity of interdisciplinary experts who can conduct MPE-type research on complex diseases. Interdisciplinary education which fully integrates pathology and epidemiology has been proposed to transform epidemiology into modern integrative population health science [80, 81, 84]. We stress the importance of considering heterogeneity in disease pathogenesis and mechanisms in not only enhancing causal inference but also advancing medicine and public health.

Acknowledgments

Funding: This work was supported by U.S. National Institutes of Health (NIH) grants [R01 CA151993 to S.O.; R35 CA197735 to S.O., and K07 CA190673 to R.N.]. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Abbreviations

CIMP	CpG island methylator phenotype
MPE	molecular pathological epidemiology
MSI	microsatellite instability
RCC	renal cell carcinoma
SNP	single nucleotide polymorphism.

REFERENCES

1. Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA. Body mass index and mortality in heart failure: a meta-analysis. *Am Heart J*. 2008; 156(1):13–22. [PubMed: 18585492]
2. Romero-Corral A, Montori VM, Somers VK, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. *Lancet*. 2006; 368(9536):666–678. [PubMed: 16920472]
3. Vemmos K, Ntaios G, Spengos K, et al. Association between obesity and mortality after acute first-ever stroke: the obesity-stroke paradox. *Stroke*. 2011; 42(1):30–36. [PubMed: 21127299]
4. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. *JAMA*. 2013; 309(1):71–82. [PubMed: 23280227]
5. Ahima RS, Lazar MA. Physiology. The health risk of obesity--better metrics imperative. *Science*. 2013; 341(6148):856–858. [PubMed: 23970691]
6. Lajous M, Bijon A, Fagherazzi G, et al. Body mass index, diabetes, and mortality in French women: explaining away a "paradox". *Epidemiology*. 2014; 25(1):10–14. [PubMed: 24270963]
7. Nguyen US, Niu J, Choi HK, Zhang Y. Commentary: effect of obesity on mortality: comment on article by Banack and Kaufman. *Epidemiology*. 2014; 25(1):2–3. [PubMed: 24296923]
8. Flanders WD, Eldridge RC, McClellan W. A nearly unavoidable mechanism for collider bias with index-event studies. *Epidemiology*. 2014; 25(5):762–764. [PubMed: 25051308]
9. Preston SH, Stokes A. Obesity paradox: conditioning on disease enhances biases in estimating the mortality risks of obesity. *Epidemiology*. 2014; 25(3):454–461. [PubMed: 24608666]

10. Banack HR, Kaufman JS. Does selection bias explain the obesity paradox among individuals with cardiovascular disease? *Ann Epidemiol.* 2015; 25(5):342–349. [PubMed: 25867852]
11. Banack HR, Kaufman JS. The obesity paradox: understanding the effect of obesity on mortality among individuals with cardiovascular disease. *Prev Med.* 2014; 62:96–102. [PubMed: 24525165]
12. VanderWeele TJ. Commentary: Resolutions of the birthweight paradox: competing explanations and analytical insights. *Int J Epidemiol.* 2014; 43(5):1368–1373. [PubMed: 25301862]
13. Ogino S, Giovannucci E. Commentary: Lifestyle factors and colorectal cancer microsatellite instability--molecular pathological epidemiology science, based on unique tumour principle. *Int J Epidemiol.* 2012; 41(4):1072–1074. [PubMed: 22596930]
14. Kuller LH, Bracken MB, Ogino S, Prentice RL, Tracy RP. The role of epidemiology in the era of molecular epidemiology and genomics: Summary of the 2013 AJE-sponsored Society of Epidemiologic Research Symposium. *Am J Epidemiol.* 2013; 178(9):1350–1354. [PubMed: 24105654]
15. Collins FS, Varmus H. A new initiative on precision medicine. *N Engl J Med.* 2015; 372(9):793–795. [PubMed: 25635347]
16. Ogino S, Nishihara R, VanderWeele TJ, et al. Molecular pathological epidemiology is essential in studying neoplastic and non-neoplastic diseases in the era of precision medicine. *Epidemiology.* in press.
17. Ogino S, Lochhead P, Chan AT, et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. *Mod Pathol.* 2013; 26(4):465–484. [PubMed: 23307060]
18. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. *J Natl Cancer Inst.* 2010; 102(6):365–367. [PubMed: 20208016]
19. Wang M, Kuchiba A, Ogino S. A Meta-Regression Method for Studying Etiological Heterogeneity Across Disease Subtypes Classified by Multiple Biomarkers. *Am J Epidemiol.* 2015; 182(3):263–270. [PubMed: 26116215]
20. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. *Gut.* 2011; 60(3):397–411. [PubMed: 21036793]
21. Begg CB, Orlow I, Zabor EC, et al. Identifying Etiologically Distinct Sub-Types of Cancer: A Demonstration Project Involving Breast Cancer. *Cancer Med.* in press.
22. Abbenhardt C, Poole EM, Kulmacz RJ, et al. Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia. *International journal of molecular epidemiology and genetics.* 2013; 4(3):140–149. [PubMed: 24046806]
23. Amirian ES, Petrosino JF, Ajami NJ, Liu Y, Mims MP, Scheurer ME. Potential role of gastrointestinal microbiota composition in prostate cancer risk. *Infectious agents and cancer.* 2013; 8(1):42. [PubMed: 24180596]
24. Araujo RF Jr, Lira GA, Guedes HG, et al. Lifestyle and family history influence cancer prognosis in Brazilian individuals. *Pathology, research and practice.* 2013; 209(12):753–757.
25. Bae JM, Kim JH, Cho NY, Kim TY, Kang GH. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. *British journal of cancer.* 2013; 109(4):1004–1012. [PubMed: 23900220]
26. Bishehsari F, Mahdavinia M, Vacca M, Malekzadeh R, Mariani-Costantini R. Epidemiological transition of colorectal cancer in developing countries: Environmental factors, molecular pathways, and opportunities for prevention. *World J Gastroenterol.* 2014; 20(20):6055–6072. [PubMed: 24876728]
27. Brandstedt J, Wangefjord S, Nodin B, Eberhard J, Jirstrom K, Manjer J. Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability. *BMC Cancer.* 2014; 14:371. [PubMed: 24885829]
28. Coppede F. The role of epigenetics in colorectal cancer. *Expert review of gastroenterology & hepatology.* 2014; 1–14.

29. Cross AJ, Moore SC, Boca S, et al. A prospective study of serum metabolites and colorectal cancer risk. *Cancer*. 2014; 120(19):3049–3057. [PubMed: 24894841]
30. Hagland HR, Soreide K. Cellular metabolism in colorectal carcinogenesis: Influence of lifestyle, gut microbiome and metabolic pathways. *Cancer Lett*. 2015; 356(2 Pt A):273–280. [PubMed: 24614287]
31. Hoffmeister M, Blaker H, Kloor M, et al. Body mass index and microsatellite instability in colorectal cancer: a population-based study. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2013; 22(12):2303–2311.
32. Hughes LA, Khalid-de Bakker CA, Smits KM, et al. The CpG island methylator phenotype in colorectal cancer: Progress and problems. *Biochim Biophys Acta*. 2012; 1825(1):77–85. [PubMed: 22056543]
33. Hughes LA, Simons CC, van den Brandt PA, et al. Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). *PLoS One*. 2011; 6(4):e18571. [PubMed: 21483668]
34. Hughes LA, Williamson EJ, van Engeland M, et al. Body size and risk for colorectal cancers showing BRAF mutation or microsatellite instability: a pooled analysis. *Int J Epidemiol*. 2012; 41(4):1060–1072. [PubMed: 22531127]
35. Ku CS, Cooper DN, Wu M, et al. Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. *Mod Pathol*. 2012; 25(8):1055–1068. [PubMed: 22522846]
36. Shaheen NJ. Editorial: what is behind the remarkable increase in esophageal adenocarcinoma? *The American journal of gastroenterology*. 2014; 109(3):345–347. [PubMed: 24594951]
37. Simons CC, van den Brandt PA, Stehouwer CD, van Engeland M, Weijenberg MP. Body Size, Physical Activity, Early-Life Energy Restriction, and Associations with Methylated Insulin-like Growth Factor-Binding Protein Genes in Colorectal Cancer. *Cancer Epidemiol Biomarkers Prev*. 2014; 23(9):1852–1862. [PubMed: 24972776]
38. Zaidi N, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV, Smans K. Lipogenesis and lipolysis: The pathways exploited by the cancer cells to acquire fatty acids. *Progress in lipid research*. 2013; 52(4):585–589. [PubMed: 24001676]
39. Zhu Y, Yang SR, Wang PP, et al. Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype. *British journal of cancer*. 2014; 110(5):1359–1366. [PubMed: 24448365]
40. Weisenberger DJ, Levine AJ, Long TI, et al. Association of the colorectal CpG island methylator phenotype with molecular features, risk factors, and family history. *Cancer Epidemiol Biomarkers Prev*. 2015; 24(3):512–519. [PubMed: 25587051]
41. Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. *Gastroenterology*. 2015; 148(1):77–87. e2. [PubMed: 25280443]
42. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. *Patholog Res Int*. 2011; 2011:902674. [PubMed: 21559209]
43. Campbell PT, Deka A, Briggs P, et al. Establishment of the cancer prevention study II nutrition cohort colorectal tissue repository. *Cancer Epidemiol Biomarkers Prev*. 2014; 23(12):2694–2702. [PubMed: 25472679]
44. Ng JM, Yu J. Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer. *Int J Mol Sci*. 2015; 16(2):2472–2496. [PubMed: 25622259]
45. Caiazza F, Ryan EJ, Doherty G, Winter DC, Sheahan K. Estrogen receptors and their implications in colorectal carcinogenesis. *Front Oncol*. 2015; 5:19. [PubMed: 25699240]
46. Campbell PT, Newton CC, Newcomb PA, et al. Association between Body Mass Index and Mortality for Colorectal Cancer Survivors: Overall and by Tumor Molecular Phenotype. *Cancer Epidemiol Biomarkers Prev*. 2015; 24(8):1229–1238. [PubMed: 26038390]
47. Li P, Wu H, Zhang H, et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. *Gut*. 2015; 64(9):1419–1425. [PubMed: 25239119]
48. Epplein M, Bostick RM, Mu L, Ogino S, Braithwaite D, Kanetsky PA. Challenges and opportunities in international molecular cancer prevention research: An ASPO Molecular

- Epidemiology and the Environment and International Cancer Prevention Interest Groups Report. *Cancer Epidemiol Biomarkers Prev.* 2014; 23(11):2613–2617. [PubMed: 25277796]
49. Ogino, S. Molecular pathological epidemiology (MPE). Overview of its paradigm and wide applicability even without tumor tissue [abstract]. *Cancer Prev Res (Phila)*; Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27–30; National Harbor, MD. 2013. CN06-01.
 50. Ogino S, Campbell PT, Nishihara R, et al. Proceedings of the second international molecular pathological epidemiology (MPE) meeting. *Cancer Causes Control.* 2015; 26(7):959–972. [PubMed: 25956270]
 51. Colussi D, Brandi G, Bazzoli F, Ricciardiello L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. *Int J Mol Sci.* 2013; 14(8):16365–16385. [PubMed: 23965959]
 52. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. *J Mol Diagn.* 2008; 10(1):13–27. [PubMed: 18165277]
 53. Bardhan K, Liu K. Epigenetics and colorectal cancer pathogenesis. *Cancers (Basel).* 2013; 5(2): 676–713. [PubMed: 24216997]
 54. Lochhead P, Chan AT, Nishihara R, et al. Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. *Mod Pathol.* 2015; 28(1):14–29. [PubMed: 24925058]
 55. Funkhouser WK Jr, Lubin IM, Monzon FA, et al. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. *J Mol Diagn.* 2012; 14(2):91–103. [PubMed: 22260991]
 56. Samowitz WS, Albertsen H, Sweeney C, et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. *J Natl Cancer Inst.* 2006; 98(23):1731–1738. [PubMed: 17148775]
 57. Limsui D, Vierkant RA, Tillmans LS, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. *J Natl Cancer Inst.* 2010; 102(14):1012–1022. [PubMed: 20587792]
 58. Nishihara R, Morikawa T, Kuchiba A, et al. A Prospective Study of Duration of Smoking Cessation and Colorectal Cancer Risk by Epigenetics-related Tumor Classification. *Am J Epidemiol.* 2013; 178(1):84–100. [PubMed: 23788674]
 59. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. *N Engl J Med.* 2013; 369(12):1095–1105. [PubMed: 24047059]
 60. Brixen LM, Bernstein IT, Bulow S, Ehrnrooth E. Survival of patients with Stage III colon cancer is improved in hereditary non-polypoid colorectal cancer compared with sporadic cases. A Danish registry based study. *Colorectal Dis.* 2013; 15(7):816–823. [PubMed: 23350633]
 61. Levin B. Why hereditary nonpolyposis colorectal carcinoma patients appear to have better survival than patients with sporadic colorectal carcinoma. *Cancer.* 1998; 83(2):201–203. [PubMed: 9669800]
 62. Peters U, Hutter CM, Hsu L, et al. Meta-analysis of new genome-wide association studies of colorectal cancer risk. *Hum Genet.* 2012; 131(2):217–234. [PubMed: 21761138]
 63. Phipps AI, Newcomb PA, Garcia-Albeniz X, et al. Association between colorectal cancer susceptibility loci and survival time after diagnosis with colorectal cancer. *Gastroenterology.* 2012; 143(1):51–4. e4. [PubMed: 22580541]
 64. Garcia-Albeniz X, Nan H, Valeri L, et al. Phenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survival. *Carcinogenesis.* 2013; 34(2):292–298. [PubMed: 23104301]
 65. Choi Y, Park B, Jeong BC, et al. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. *International journal of cancer. Journal international du cancer.* 2013; 132(3):625–634. [PubMed: 22610826]
 66. Hakimi AA, Furberg H, Zabor EC, et al. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. *J Natl Cancer Inst.* 2013; 105(24):1862–1870. [PubMed: 24285872]
 67. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. *Nat Rev Cancer.* 2007; 7(10):763–777. [PubMed: 17882277]

68. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. *N Engl J Med.* 2000; 343(19):1350–1354. [PubMed: 11070098]
69. McDonald KL, Rapkins RW, Olivier J, et al. The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients. *European journal of cancer.* 2013; 49(2):360–368. [PubMed: 22975219]
70. Ogino S, Hazra A, Tranah GJ, et al. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. *Carcinogenesis.* 2007; 28(9):1985–1990. [PubMed: 17621591]
71. Hawkins NJ, Lee JH, Wong JJ, Kwok CT, Ward RL, Hitchins MP. MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. *Mod Pathol.* 2009; 22(12):1588–1599. [PubMed: 19734844]
72. Gao Q, Tsoi KK, Hirai HW, et al. Serrated polyps and the risk of synchronous colorectal advanced neoplasia: a systematic review and meta-analysis. *Am J Gastroenterol.* 2015; 110(4):501–509. quiz 10. [PubMed: 25756237]
73. Field AE, Camargo CA Jr, Ogino S. The merits of subtyping obesity: one size does not fit all. *JAMA.* 2013; 310(20):2147–2148. [PubMed: 24189835]
74. Ikramuddin S, Livingston EH. New insights on bariatric surgery outcomes. *JAMA.* 2013; 310(22):2401–2402. [PubMed: 24189645]
75. van Winkel R. Aetiological stratification as a conceptual framework for gene-by-environment interaction research in psychiatry. *Epidemiol Psychiatr Sci.* 2015; 24(1):6–11. [PubMed: 25693861]
76. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation.* 2013; 128(16):e240–e319. [PubMed: 23741058]
77. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. *J Natl Compr Canc Netw.* 2011; 9(Suppl 5):S1–S32. quiz S3.
78. Reimers MS, Zeestraten EC, Kuppen PJ, Liefers GJ, van de Velde CJ. Biomarkers in precision therapy in colorectal cancer. *Gastroenterol Rep (Oxf).* 2013; 1(3):166–183. [PubMed: 24759962]
79. Bayer R, Galea S. Public Health in the Precision-Medicine Era. *N Engl J Med.* 2015; 373(6):499–501. [PubMed: 26244305]
80. Ogino S, King EE, Beck AH, Sherman ME, Milner DA, Giovannucci E. Interdisciplinary Education to Integrate Pathology and Epidemiology: Towards Molecular and Population- Level Health Science. *Am J Epidemiol.* 2012; 176(8):659–667. [PubMed: 22935517]
81. Kuller LH. Invited Commentary: The 21st Century Epidemiologist--A Need for Different Training? *Am J Epidemiol.* 2012; 176(8):668–671. [PubMed: 22935514]
82. VanderWeele TJ, Knol MJ. Interactions and complexity: Goals and limitations. *Epidemiol Method.* 2014; 3(1):79–81.
83. Song M, Nishihara R, Wang M, et al. Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. *Gut.* in press.
84. Ogino S, Beck AH, King EE, Sherman ME, Milner DA, Giovannucci E, Ogino, et al. Respond to "The 21st Century Epidemiologist". *Am J Epidemiol.* 2012; 176(8):672–674. [PubMed: 22935516]

Fig. 1. The apparent paradoxical associations in colorectal cancer, renal cell carcinoma, and glioblastoma (malignant brain tumor), utilizing molecular pathological epidemiology (MPE) approach and literature data. a. Lynch syndrome is associated with incidence of colorectal cancer with high levels of microsatellite instability (MSI-high), and MSI-high cancer is associated with better prognosis among patients with colorectal cancer. Hence, the carrier status of Lynch syndrome mutation is associated with higher colorectal cancer risk, but with better prognosis among colorectal cancer patients. b. The major G allele of the rs4939827 *SMAD7* polymorphism is associated with colorectal cancer with earlier stage, and earlier cancer stage is associated with better prognosis among patients with colorectal cancer. The major G allele of the rs4939827 *SMAD7* polymorphism is associated with higher colorectal cancer risk, but with better prognosis among colorectal cancer patients. c. Obesity is associated with a subtype of renal cell carcinoma (RCC) characterized by low-stage, low-grade, and *FASN* non-upregulation, and all of these features are associated with better prognosis among RCC patients. Hence, obesity is associated with higher RCC risk, but with better prognosis among RCC patients. d. The minor T allele of the rs16906252 polymorphism in the *MGMT* promoter region is associated with loss of *MGMT* expression in glioblastoma, and loss of *MGMT* expression is associated with better prognosis among

patients with glioblastoma. Hence, the minor T allele of rs16906252 polymorphism contributes to pathogenesis of glioblastoma, but is associated with better prognosis among glioblastoma patients.

MSI, microsatellite instability.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript